Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors medexus.com/en_US/news-media…
195
Medexus Announces Fiscal Q1 2027 Results With Strongest Quarter of Product-Level Performance of GRAFAPEX (Treosulfan) to Date medexus.com/en_US/investors/…
Medexus Provides Business Update on GRAFAPEX (treosulfan) for Injection, Capital Allocation, and Investor Conference Participation medexus.com/en_US/investors/…
Medexus Announces Fiscal Q3 2026 Results, Driven by Continued Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection medexus.com/en_US/investors/…
Medexus Schedules Third Fiscal Quarter 2026 Conference Call medexus.com/en_US/investors/…
2
170
For more than a decade IXINITY® has been a treatment option for those living with hemophilia B. FDA-approved in April 2015, we celebrate the 10th "Approve-iversary" of #IXINITY by looking back into the archives. Please see Full Prescribing Information at IXINITY.com
2
262
Medexus Announces Normal Course Issuer Bid, or NCIB, for Its Common Shares
Read the full press release: medexus.com/en_US/news-media…
#MedexusInc $MDP.CA $MEDXF
Medexus Announces US$51.0 million in New Credit Facilities and Intention to Commence Normal Course Issuer Bid, or NCIB, for its Common Shares
Read the full press release: medexus.com/en_US/investors/…
#MedexusInc $MDP.CA $MEDXF
Medexus Announces Fiscal Q2 2026 Results, Driven by Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection
Read the full press release: medexus.com/en_US/news-media…
#MedexusInc $MDP.CA $MEDXF
3
275
Medexus Schedules Second Fiscal Quarter 2026 Conference Call
Read the full press release:medexus.com/en_US/investors/…
#MedexusInc $MDP.CA $MEDXF
1
1
196
Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors medexus.com/en_US/investors/…
1
2
155
Medexus Announces Fiscal Q1 2026 Results, Including Positive Results from US Launch of GRAFAPEX (treosulfan) for Injection medexus.com/en_US/investors/…
5
242
Medexus Schedules First Fiscal Quarter 2026 Conference Call medexus.com/en_US/investors/…
3
187
GRAFAPEX (treosulfan) for Injection Receives CMS Approval of New Technology Add-On Payment (NTAP) for Eligible Cases in CMS's Fiscal Year 2026 medexus.com/en_US/investors/…
Medexus Announces Strong Fiscal Year 2025 Results, Including Initial Results from Launch of GRAFAPEX (treosulfan) for Injection in the United States medexus.com/en_US/news-media…
1
173
Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2025 Conference Call medexus.com/en_US/news-media…
The Public Prescription Drug Insurance Plan of the Régie de l'Assurance Maladie du Québec, or RAMQ, will now reimburse eligible claims made for Trecondyv®.
"This development is another important reimbursement milestone for Trecondyv® because we have now achieved public reimbursement of Trecondyv® in Canada's three most populous provinces, representing around three quarters of Canadians," said Richard Labelle, Medexus COO
2
1
279
Review our April 17 news release for more information: medexus.com/en_US/news-media…
2
259
Medexus Successfully Completes Agreement for Public Reimbursement of Trecondyv (treosulfan for injection) in Quebec, Canada medexus.com/en_US/investors/…




